PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ: STEM) today announced it will begin a patent-reexamination process with the U.S. Patent and Trademark Office (PTO) following the agency’s decision, which was expected, to preliminarily reject all claims in the company’s four patents which are the subject of its lawsuit against Neuralstem, Inc.
